Hong Kong: Doubling Down on Clinical Research
Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research…
Patrick is the managing editor of PharmaBoardroom
Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
Pfizer CEO Albert Bourla is the pharma executive with the biggest impact on social media, according to a new study. While busy industry leaders may not currently place social media…
A roundup of some of the top stories from the Indian pharma industry including the suspension of the National Medical Commission’s (NMC) guidelines making the prescription of generic drugs mandatory;…
Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and…
As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
Janssen has the lofty aim of reaching USD 60bn dollars in sales by 2025, an 8bn increase on the 2021 figure, despite some high-profile losses of exclusivity and the spin-off…
The latest news from UK healthcare and life sciences, including the safety review of Novo Nordisk’s GLP-1 receptor agonists; VaxEquity’s grant to scale up RNA vaccine manufacturing; AstraZeneca/Quell Therapeutics cell…
There have been both ups and downs in AbbVie’s recent history. After proving its staying power with the celebration of its 10-year anniversary as an independent company spun off from…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
See our Cookie Privacy Policy Here
